SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has appointed Sarah M. Romano as chief financial officer, effective Aug. 3, 2026. Based in the United States, Romano brings more than two decades of finance leadership experience in the medical technology and life sciences sectors and will help lead the company’s financial operations as it advances its global expansion strategy, including pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system.
Most recently, Romano served as chief financial officer of Vicarious Surgical, where she led financial and operational initiatives to reduce cash burn, strengthen the balance sheet and support strategic objectives. She previously held CFO roles at Entero Therapeutics and Kiora Pharmaceuticals, raising more than $100 million through public and private financings while overseeing strategic transactions, SEC reporting and investor relations. According to the full press release, her experience in capital raising and financial management is expected to be instrumental as SSII seeks to scale its operations and bring its robotic surgical solutions to broader markets.
SS Innovations International develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
The appointment of Romano signals the company's commitment to strengthening its financial leadership as it prepares for a key regulatory milestone. The pursuit of U.S. FDA approval for the SSi Mantra system could open a significant market opportunity, given the increasing adoption of robotic-assisted surgery globally. If approved, the system would compete with established platforms but at a potentially lower cost, aligning with the company's mission to democratize robotic surgery.
Investors and industry observers will be watching how Romano's track record in capital management and strategic financing translates to SSII's growth trajectory. The company's focus on cost-effective solutions and global expansion could reshape access to advanced surgical technologies, particularly in underserved regions. With the new CFO in place, SS Innovations is positioned to navigate the financial complexities of regulatory approval and market entry.
